Cytokinetics (CYTK) Reports In-Line Q3 EPS
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $80.01 --0%
EPS Growth %: -46.4%
Financial Fact:
Research and development: 19.34M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -46.4%
Financial Fact:
Research and development: 19.34M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($0.51), in-line with the analyst estimate of ($0.51). Revenue for the quarter came in at $6.22 million versus the consensus estimate of $5.19 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Crown Crafts (CRWS) Reports Q4 EPS of $0.03
- KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
